The long term goal of this research project is to elucidate the immunological mechanisms by which NK cells regulate T cell responses during infections with intracellular bacteria. Human monocytotropic ehrlichiosis (HME) is a highly prevalent life-threatening tick-borne disease in North America caused by E. chaffeensis. The infection can be subclinical or fatal, mimicking toxic shock syndrome. Although management of this disease relies on doxycycline, there is a high rate of treatment failure when the drug is administered late in infection. Our extensive murine studies indicated that fatal Ehrlichia-inducedshock is due to CD8+ T cell-mediated immunopathology. IFN-gamma producing-CD4+ Th1 cells are critical for the elimination of Ehrlichia; however, these cells undergo suppression and late apoptosis during fatal disease. We recently demonstrated that NK cells impair effective bacterial elimination and mediate tissue injury during fatal Ehrlichia-induced shock. However, the immunoregulatory mechanisms that account for the pathogenic role of NK cells in Ehrlichia- induced shock remain unknown. We hypothesize that NK cells negatively regulate the generation of protective anti-erhrlichial immune responses by suppressing CD4+ Th1 cell responses, while promoting the induction of pathogenic CD8+ T cells and tissue injury during fatal Ehrlichia-induced toxic shock. We will test this hypothesis using three specific aims.
In Aim1, we will determine the impact of NK cells on the functions of protective CD4+ Th1 cells during fatal ehrlichial infection.
In Aim 2, we will identify the molecular mechanisms by which NK cells contribute to the pathogenesis of Ehrlichia-induced toxic shock.
In Aim 3, we will characterize the NK cell responses throughout the course of Ehrlichia infection in humans. We will carry out these aims by: 1) measuring the differences in expansion and effector functions of CD4+ T cells and CD8+ T cells in Ehrlichia- infected NK-depleted mice or sham controls; 2) comparing the proliferation and cytokine production of effector CD4+T cells when co-cultured in vitro with NK cells derived from lethally- or non-lethally infected mice in the presence or absence of Ehrlichia-infected antigen presenting cells (APCs); 3) comparing CD4+ T cell and CD8+ T cell responses in irradiated bone marrow mouse chimeras, in which IL-10 will be only expressed by non-hematopoietic cells or non B/T lymphocyte-innate hematopoietic cells including NK cells and APCs; and 4) comparing NK and T cell responses in patients with severe and mild ehrlichiosis and determine whether in vitro depletion of human NK cells alters the proliferation and functions of human CD4+T cells in these patients. HME is not only an emerging public health concern, but represents a model for toxic or septic shock caused by other bacteria. Therefore, knowledge generated herein will facilitate rational development of novel therapeutics against infection-induced sepsis.

Public Health Relevance

Human monocytic ehrlichiosis, the most prevalent life-threatening tick- borne disease in North America, usually has a poor clinical outcome due, in part to, the lack of a vaccine and a less than adequate therapy. This proposal will identify, for the first time, the role of NK cells in regulating the anti-Ehrlichia activity of CD4+ T cells (criical for clearing bacterial infection), and in generating the pathogenic CD8 T cell responses that cause tissue damage and subsequent multi-organ failure. The results obtained from this study will provide a solid foundation for the timely development of an effective immune-based therapy for treatment of this fatal disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI097679-01A1
Application #
8510784
Study Section
Host Interactions with Bacterial Pathogens Study Section (HIBP)
Program Officer
Mukhopadhyay, Suman
Project Start
2012-08-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$395,465
Indirect Cost
$128,030
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213